JAGSNPHARM.NS Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 май 2024 @ 12:59):

Jagsonpal Pharmaceuticals Limited develops and manufactures bulk drugs and pharmaceutical formulations in the areas of women health, pain and analgesics, and general medicine...

Stats
Объем за сегодня	23 215.00
Средний объем	41 542.00
Рыночная капитализация	9.08B
EPS	INR0 ( 2024-02-02 )
Дата следующего отчета о доходах	( INR0 ) 2024-05-20
Last Dividend	INR5.00 ( 2023-08-21 )
Next Dividend	INR0 ( N/A )
P/E	36.98
ATR14	INR0.385 (0.11%)

Объем Корреляция

Длинно: -0.03 (neutral)

Кратко: 0.09 (neutral)

Signal:(31.078) Neutral

Jagsonpal Pharmaceuticals Корреляция

10 Самые положительные корреляции
20MICRONS.NS	0.912
MUTHOOTFIN.NS	0.91
21STCENMGM.NS	0.902
DELPHIFX.NS	0.889
STAR.NS	0.887
ICICIPHARM.NS	0.887
KCP.NS	0.879
MEDICAMEQ.NS	0.877
IGPL.NS	0.876
PVP.NS	0.873

10 Самые отрицательные корреляции
RAJRILTD.NS	-0.926
4THDIM.NS	-0.912
LTGILTBEES.NS	-0.876
SYMPHONY.NS	-0.869
SRTRANSFIN.NS	-0.84
ISMTLTD.NS	-0.833
GNA.NS	-0.832
SHRIRAMEPC.NS	-0.807
JSL.NS	-0.801

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Jagsonpal Pharmaceuticals Корреляция - Валюта/Сырье

0.05
( neutral )

-0.10
( neutral )

-0.48
( neutral )

-0.23
( neutral )

0.26
( neutral )

0.07
( neutral )

Jagsonpal Pharmaceuticals Финансовые показатели

Annual	2022
Выручка:	INR2.37B
Валовая прибыль:	INR1.44B (60.67 %)
EPS:	INR10.20

FY	2022
Выручка:	INR2.37B
Валовая прибыль:	INR1.44B (60.67 %)
EPS:	INR10.20

FY	2022
Выручка:	INR2.26B
Валовая прибыль:	INR1.30B (57.49 %)
EPS:	INR7.48

FY	2021
Выручка:	INR1.88B
Валовая прибыль:	INR1.07B (56.92 %)
EPS:	INR6.51

Financial Reports:

No articles found.

Jagsonpal Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR5.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Jagsonpal Pharmaceuticals Dividend Information - Dividend Junior

Dividend Sustainability Score: 4.51 - low (49.85%) | Divividend Growth Potential Score: 5.54 - Stable (10.70%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR3.75	2003-05-30
Last Dividend	INR5.00	2023-08-21
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	21	--
Total Paid Out	INR19.95	--
Avg. Dividend % Per Year	1.32%	--
Score	2.75	--
Div. Sustainability Score	4.51
Div.Growth Potential Score	5.54
Div. Directional Score	5.02	--

Next Divdend (Est)
(2024-07-05)

INR5.77 Estimate 3.12 %

Dividend Stability

0.25 Very Poor

Dividend Score

2.75

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR0.100	0.36%
2019	INR0.250	0.79%
2020	INR0.500	1.95%
2021	INR5.00	6.21%
2022	INR0	0.00%
2023	INR5.00	1.36%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
TATVA.NS	Dividend Junior	2023-09-08	Annually	3	0.04%
NUCLEUS.NS	Dividend Junior	2023-07-07	Annually	22	1.41%
INDUSINDBK.NS	Dividend Junior	2023-06-02	Annually	23	0.56%
COLPAL.NS	Dividend Knight	2023-05-19	Semi-Annually	18	1.38%
SBIN.NS	Dividend Junior	2023-05-31	Sporadic	29	0.99%
MAHSEAMLES.NS	Dividend Junior	2023-08-14	Annually	21	0.80%
GODFRYPHLP.NS	Dividend Junior	2023-08-11	Annually	24	1.52%
AURIONPRO.NS	Dividend Junior	2023-09-22	Sporadic	19	0.36%
TOUCHWOOD.NS	Dividend Junior	2023-09-22	Annually	6	0.15%
PGIL.NS	Dividend Junior	2023-09-01	Annually	17	1.08%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.111	1.500	7.78	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.149	1.500	9.45	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	39.98	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	5.34	2.00	8.22	10.00	[0 - 30]
freeCashFlowPerShareTTM	5.34	2.00	7.33	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.609	1.000	3.19	3.19	[0.2 - 0.8]
operatingProfitMarginTTM	0.144	1.000	9.13	9.13	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.51

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	38.02	1.000	6.26	0	[1 - 100]
returnOnEquityTTM	0.149	2.50	9.65	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	5.34	2.00	8.22	10.00	[0 - 30]
dividendYielPercentageTTM	1.410	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	5.34	2.00	8.22	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	3.59	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0636	1.000	-0.909	0	[0.1 - 0.5]
Total Score				5.54

Jagsonpal Pharmaceuticals

Jagsonpal Pharmaceuticals Limited develops and manufactures bulk drugs and pharmaceutical formulations in the areas of women health, pain and analgesics, and general medicine. It offers general medicines, such as allergy management, immunity and cell protection, gut and mind management, anti-infectives, and dentist and ENT range products; and women's healthcare products, including pregnancy care, and dysfunctional uterine bleeding complications and management products. The company also provides pain and analgesics products in the areas of pain management, and bone and joint care. It offers drugs in the form of tablets, capsules, and syrups. The company was founded in 1964 and is based in New Delhi, India. Jagsonpal Pharmaceuticals Limited is a subsidiary of Aresko Progressive Private Limited.